SFX by Ex Libris Inc.

Title:	A vaccine targeting mutant IDH1 induces antitumour immunity
Source:	Nature [0028-0836] Schumacher, T yr:2014

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Kloosterhof, Nanne K. "Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?" The lancet oncology 12.1 (2010): 83-91.
description	2.	Houghton, Alan N. "CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems." Vaccine 22.13/14 (2004): 1700-1708.
description	3.	Wolfel, T. "A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma." Science 269.5228 (1995): 1281-1284.
description	4.	Thompson, John F. "Cutaneous melanoma." The lancet 365.9460 (2005): 687-701.
description	5.	Boog, C J J. "Abolition of specific immune response defect by immunization with dendritic cells." Nature 318.6041 (1985): 59-62.
description	6.	Lopez, Giselle Y. "IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain." Biochemical and biophysical research communications 398.3 (2010): 585-587.
description	7.	Thompson, John F F. "Cutaneous melanoma." The lancet 365.9476 (2005): 2003-701.
description	8.	Zhou, J. "Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy." Journal of immunotherapy 28.1 (2005): 53-62.
description	9.	Bhardwaj, N. "Dendritic cells are potent antigen-presenting cells for microbial superantigens." The Journal of experimental medicine 175.1 (1992): 267-73.
description	10.	Edele, F. "Efficiency of Dendritic Cell Vaccination against B16 Melanoma Depends on the Immunization Route." PLoS ONE 9.8 (2014): 1-.
description	11.	Jaffee, Elizabeth M. "Enhanced immune priming with spatial distribution of paracrine cytokine vaccines." Journal of immunotherapy with emphasis on tumor immunology 19.3 (1996): 176-83.
description	12.	Toedt, G. "Molecular signatures classify astrocytic gliomas by IDH1 mutation status." International journal of cancer 128.5 (2010): 1095-1103.
description	13.	Kapadia D, D. "CTLA-4 blockade: autoimmunity as treatment." Journal of clinical oncology 23.35 (2005): 8926-8.
description	14.	Fioretti, D. "DNA vaccines: developing new strategies against cancer." Journal of biomedicine and biotechnology 2010 (2010): 174378-174378.
description	15.	Casanovas, R. "Immunological classification of acute myeloblastic leukemias: relevance to patient outcome." Leukemia 17.3 (2003): 515-527.
description	16.	Sanson, M. "Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas." Journal of clinical oncology 27.25 (2009): 4150-4154.
description	17.	Diffey, B. "The future incidence of cutaneous melanoma within the UK." British journal of dermatology 151.4 (2004): 868-872.
description	18.	Gould, R. "Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis." Journal of the National Cancer Institute 101.7 (2009): 452-74.
description	19.	Quezada, Sergio A A. "Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma." The Journal of experimental medicine 205.9 (2008): 2125-38.
description	20.	Youl, P. "Melanoma in adolescents: a case-control study of risk factors in Queensland, Australia." International journal of cancer 98.1 (2002): 92-8.